<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03685331</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 21118</org_study_id>
    <nct_id>NCT03685331</nct_id>
  </id_info>
  <brief_title>HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer</brief_title>
  <official_title>Harnessing Olaparib, Palbociclib and Endocrine Therapy: A Phase I/II Trial of Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer (HOPE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this research study is to learn whether the investigational combination&#xD;
      of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive&#xD;
      breast cancer and BRCA1 or BRCA2 mutations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The phase I component is a dose-escalation study. Dose escalation will follow a 3+3 design. An additional cohort of at least 36 patients (total number of patients in phase I and phase II = 54) will be included on the single-arm, non-randomized phase II portion of this clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From first dose of protocol therapy to progression or death due to any cause, whichever comes first, an estimated average of 7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>From first dose of protocol therapy to progression or death due to any cause, whichever comes first, an estimated average of 7 months</time_frame>
    <description>Includes complete and partial response as per RECIST 1.1 criteria. Overall response rate will be defined as the proportion of patients within the efficacy analysis set that experience a complete or partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-week clinical benefit rate</measure>
    <time_frame>From the date of study treatment until the date of progression, an estimated average of 7 months</time_frame>
    <description>Defined as the proportion of patients within the efficacy analysis set that experience clinical benefit ≥24 weeks.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Locally Advanced Breast Cancer</condition>
  <condition>Advanced Breast Cancer</condition>
  <condition>BRCA2 Mutation</condition>
  <condition>BRCA1 Mutation</condition>
  <arm_group>
    <arm_group_label>Phase I Level 0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(28-day cycle)&#xD;
Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 75 mg by mouth daily, days 1-21, beginning at cycle 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(28-day cycle)&#xD;
Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 100 mg by mouth daily, days 1-21, beginning at cycle 1&#xD;
Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(28-day cycle)&#xD;
Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 125 mg by mouth daily, days 1-21, beginning at cycle 1&#xD;
Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(28-day cycle) Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly once monthly on Day 1 of each cycle + 500 mg intramuscularly on Cycle 1 Day 15; palbociclib dose as per maximum tolerated dose determined during Phase I, by mouth daily, days 1-21&#xD;
Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Combination of palbociclib, olaparib, and fulvestrant.</description>
    <arm_group_label>Phase I Level 0</arm_group_label>
    <arm_group_label>Phase I Level 1</arm_group_label>
    <arm_group_label>Phase I Level 2</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>Combination of palbociclib, olaparib, and fulvestrant.</description>
    <arm_group_label>Phase I Level 0</arm_group_label>
    <arm_group_label>Phase I Level 1</arm_group_label>
    <arm_group_label>Phase I Level 2</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Combination of palbociclib, olaparib, and fulvestrant.</description>
    <arm_group_label>Phase I Level 0</arm_group_label>
    <arm_group_label>Phase I Level 1</arm_group_label>
    <arm_group_label>Phase I Level 2</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females/males ≥ age 18&#xD;
&#xD;
          -  Germline or somatic deleterious or suspected deleterious mutation in BRCA1 or BRCA2&#xD;
&#xD;
          -  Metastatic or locally advanced unresectable breast cancer that is ER and/or PR&#xD;
             positive (&gt;1%) and HER2 nonamplified&#xD;
&#xD;
          -  Prior treatment with 0-2 prior lines of chemotherapy for metastatic breast cancer&#xD;
&#xD;
          -  Regarding prior platinum-based chemotherapy:&#xD;
&#xD;
               1. Patients who received prior platinum-based chemotherapy in the adjuvant or&#xD;
                  neoadjuvant setting for breast cancer are eligible if treatment was completed at&#xD;
                  least 12 months prior to diagnosis of metastatic disease.&#xD;
&#xD;
               2. Patients who received platinum for advanced breast cancer are eligible to enter&#xD;
                  the study provided there was no evidence of disease progression during the&#xD;
                  platinum chemotherapy.&#xD;
&#xD;
               3. Patients who received prior platinum-based as a potentially curative treatment&#xD;
                  for a prior non-breast cancer (e.g., ovarian cancer) with no evidence of disease&#xD;
                  for 5 years or greater prior to study entry are permitted.&#xD;
&#xD;
          -  Deemed a candidate for endocrine therapy (any prior endocrine therapy is permitted; no&#xD;
             prior endocrine therapy is also permitted)&#xD;
&#xD;
          -  Adequate organ and bone marrow function&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  At least one measurable disease or disease that can be assessed by CT or MRI&#xD;
&#xD;
          -  Life expectancy ≥ 16 weeks&#xD;
&#xD;
          -  Postmenopausal as defined below. Women who are on pharmacologic ovarian suppression&#xD;
             must have two negative urine or serum pregnancy tests: one during screening (within 28&#xD;
             days prior to study treatment) and one within 7 days prior to commencing treatment.&#xD;
&#xD;
        Postmenopausal is defined as one of the below:&#xD;
&#xD;
          -  Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments&#xD;
&#xD;
          -  Follicle stimulating hormone (FSH) levels in the post-menopausal range for women under&#xD;
             50&#xD;
&#xD;
          -  radiation-induced oophorectomy with last menses &gt;1 year ago&#xD;
&#xD;
          -  chemotherapy-induced menopause with &gt;1 year interval since last menses&#xD;
&#xD;
          -  bilateral oophorectomy or hysterectomy&#xD;
&#xD;
          -  on luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical&#xD;
             practice standards as pharmacologic ovarian suppression&#xD;
&#xD;
          -  Female patients of childbearing potential (not post-menopausal as defined above) must&#xD;
             agree to the use of two highly effective forms of contraception in combination&#xD;
             throughout the period of taking study treatment and for 1 month after last dose of&#xD;
             study drug(s) to prevent pregnancy.&#xD;
&#xD;
          -  Male patients and their sexual partners of childbearing potential must agree to the&#xD;
             use of two highly effective forms of contraception in combination throughout the&#xD;
             period of taking study treatment and for 3 months after last dose of study drug(s) to&#xD;
             prevent pregnancy in a partner.&#xD;
&#xD;
          -  Willing to comply with study requirements and procedures including use of appropriate&#xD;
             contraception, willingness to discontinue herbal preparations / medications, and study&#xD;
             biopsy if archival tissue is not available&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Involvement in study planning or conduct&#xD;
&#xD;
          -  Regarding prior olaparib or palbociclib,&#xD;
&#xD;
             a) Phase II: Patients who previously progressed on olaparib or palbociclib for&#xD;
             metastatic breast cancer treatment are excluded&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product during the&#xD;
             last 3 weeks&#xD;
&#xD;
          -  Systemic chemotherapy or radiotherapy (except palliative) within 3 weeks of start of&#xD;
             study treatment&#xD;
&#xD;
          -  Major surgery within 2 weeks of start of study treatment&#xD;
&#xD;
          -  Other malignancy within the last 5 years with exceptions listed in the protocol&#xD;
&#xD;
          -  Concomitant strong or moderate CYP3A inhibitors/ inducers&#xD;
&#xD;
          -  Persistent toxicity of prior cancer therapy that is grade ≥ 2 except for alopecia or&#xD;
             neuropathy&#xD;
&#xD;
          -  MDS or features suggestive of MDS/AML&#xD;
&#xD;
          -  Symptomatic uncontrolled brain metastases&#xD;
&#xD;
          -  Patients considered to be at poor medical risk&#xD;
&#xD;
          -  QTc &gt;470 msec on 2 or more time points or a family history of long QT syndrome&#xD;
&#xD;
          -  Unable to swallow or absorb oral medication&#xD;
&#xD;
          -  Immunocompromised patients&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Hypersensitivity to olaparib, palbociclib, fulvestrant, or any excipients of these&#xD;
             products&#xD;
&#xD;
          -  Known active hepatitis&#xD;
&#xD;
          -  Prior bone marrow transplant&#xD;
&#xD;
          -  Whole blood transfusions 120 days prior to signing consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Payal D. Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandra Torres</last_name>
    <phone>855-216-0098</phone>
    <email>PennCancerTrials@emergingmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Payal D. Shah, MD</last_name>
      <phone>855-216-0098</phone>
      <email>PennCancerTrials@emergingmed.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>September 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2-negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

